Social Media Ideas for Novo Nordisk A/S

Novo Nordisk: The Oral Wegovy Promise

Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future

Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.

<![CDATA[Pharmaceutical Executive Daily: Novo Nordisk Files Lawsuit Against Eli Lilly]]>

Novo Nordisk: Initiating Buy, Calling The Bottom

<![CDATA[Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons]]>

Novo Nordisk shares in hot water after disappointing trial

Novo Nordisk sues Eli Lilly over ‘deliberately false’ weight-loss drug ads

Danish group claims rival used outdated data to support claims that its products were more effective than Wegovy

Novo Asks NJ Judge To Stop Lilly's 'Deceptive' GLP-1 Ads

Novo Nordisk Inc. asked a New Jersey federal court Friday to block rival Eli Lilly & Co. from running ads allegedly comparing their respective GLP-1 drugs using "outdated" clin...

Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads

Danish pharma company says Eli Lilly using outdated trial data to make its weight-loss drugs appear more effectiveOzempic maker Novo Nordisk said on Tuesday it is suing arch US riv...

Novo's False Ad Suit Against Eli Lilly Ramps Up GLP-1 Rivalry

Pharmaceutical giant Novo Nordisk Inc. slapped rival Eli Lilly & Co. with a false advertising suit in New Jersey federal court Tuesday, calling a marketing campaign for the riv...

Novo Nordisk: Too Late For A Great Opportunity

Novo Nordisk sues Eli Lilly, alleges deceptive advertising for Zepbound

Novo Nordisk filed a lawsuit against Eli Lilly & Co. accusing the manufacturer of Zepbound of deceptive advertising for allegedly comparing high doses of its drug to low doses...

Novo Nordisk sues rival Eli Lilly over ‘misleading' weight-loss drug advertising

Two of the world’s biggest pharmaceutical companies are headed to court after Novo Nordisk, the maker of Ozempic and a pioneer in diabetes and obesity treatments, sued rival Eli Li...

Herz-Medikament: Novo Nordisk mit Entwicklungsfehlschlag – Aktienkurs sackt ab

Der dänische Pharmariese scheitert mit seinem Herzmittel Ziltivekimab in einer zulassungsrelevanten Studie. Es hätte ein milliardenschweres Umsatzpotenzial haben können.

Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data

Novo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing th...

Novo Nordisk’s CFO on the oral Wegovy rollout and beyond

Novo Nordisk CFO Karsten Munk Knudsen joins “The Top Line” to discuss oral Wegovy’s rollout, the company’s raised outlook, why he’s still optimistic about CagriSema and more.

Pharmaindustrie: Novo Nordisk erzielt Erfolge mit Abnehmspritze bei Kindern

Weltweit steigt die Zahl fettleibiger Kinder. Novo Nordisk liefert nun erste Studiendaten zur Wirkung von Semaglutid im Kindesalter.

Novo Nordisk: Novo Nordisks Abnehmpille startet in Deutschland – doch die Börse glaubt nicht daran

Deutschland ist das erste EU-Land, in dem die Abnehmpille auf den Markt kommt. Tausende Menschen stehen bereits auf Wartelisten. Doch Analysten sehen langfristig die Konkurrenz vor...

Novo Nordisk sues Eli Lilly over GLP-1 drug ads

Novo Nordisk sued Eli Lilly, alleging misleading ads unfairly compare doses of Zepbound and Mounjaro with Wegovy and Ozempic. The post Novo Nordisk sues Eli Lilly over GLP-1 drug a...

‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth

Novo Nordisk CFO Karsten Munk Knudsen spoke to Fierce the morning the company unveiled its second-quarter earnings, reflecting on Novo’s “roller coaster” financial journey, the pre...

Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail

A phase 3 trial of Novo Nordisk’s ziltivekimab has missed its primary endpoint, denting the prospects of a molecule analysts tipped to generate blockbuster sales and diversify the...

"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means fo...

Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.

Novozymes A/S 2026 Q2 - Results - Earnings Call Presentation

Novo Nordisk and Amazon sign AI drug discovery pact, launch London innovation hub

Novo Nordisk and Amazon Web Services will partner to leverage AI and accelerate drug discovery.